Table 3.
Univariate and multivariable Cox proportional hazards model analyses of PFS and OS in TC group.
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p | HR (95%CI) | p | |
| High vs. Low IL-6 | 2.594 (1.345-5.002) | 0.004* | 2.102 (1.077-4.103) | 0.029* | 4.437 (1.500-13.123) | 0.007* | 3.309 (1.027-10.660) | 0.045* |
| Male vs. Female | 1.490 (0.741-2.994) | 0.263 | 1.471 (0.570-3.795) | 0.425 | ||||
| Age ≥ 65 vs.< 65 | 0.983 (0.535-1.809) | 0.957 | 1.008 (0.431-2.357) | 0.986 | ||||
| ECOG PS 3 vs. ≤ 2 | 0.429 (0.103-1.786) | 0.245 | 0.509 (0.068-3.803) | 0.510 | ||||
| TNM IV vs. III | 2.600 (1.343-5.035) | 0.005* | 1.813 (0.911-3.610) | 0.090 | 3.665 (1.346-9.977) | 0.011* | 2.904 (0.812-10.384) | 0.101 |
| Surgery vs. no | 0.564 (0.294-1.085) | 0.086 | 0.690 (0.284-1.676) | 0.412 | ||||
| IrAEs vs. non-irAE | 1.080 (0.585-1.992) | 0.806 | 0.749 (0.324-1.732) | 0.499 | ||||
| ICIs monotherapy | Reference | Reference | Reference | |||||
| ICIs & chemotherapy | 0.153 (0.020-1.179) | 0.072 | 0.052 (0.006-0.452) | 0.007* | 0.094 (0.010-0.875) | 0.038* | ||
| ICIs & targeted | 0.468 (0.054-4.041) | 0.490 | 0.341 (0.037-3.123) | 0.341 | 0.048 (0.004-0.619) | 0.020* | ||
| Triple therapy | 0.303 (0.036-2.537) | 0.270 | 0.086 (0.008-0.879) | 0.039 | 0.078 (0.007-0.917) | 0.042* | ||
| Treatment line ≥ 3 | 8.943 (4.155-19.251) | 0.000* | 6.601 (3.042-14.321) | 0.000* | 11.529 (4.715-28.190) | 0.000* | 13.468 (3.752-48.342) | 0.000* |
| GAC vs. ESSC | 0.912 (0.480-1.731) | 0.778 | 0.983 (0.397-2.430) | 0.970 | ||||
ECOG PS, Eastern Cooperative Oncology Group performance status; ICIs, Immune checkpoint inhibitors; Triple therapy, immunotherapy combination chemotherapy with targeted therapy; ESSC, esophageal squamous cell carcinoma; GAC, gastric adenocarcinoma; irAEs, immune-related adverse events; HR, hazard ratio; CI, confidence interval. *p < 0.05.